Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 5;10(10):1662. doi: 10.3390/vaccines10101662

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

SARS-CoV-2 binding antibody levels at 1 and 3 months after two doses of the ChAdOx-nCoV-19 vaccine in cancer patients stratified by treatment given (n = 137) compared to healthy controls (n = 84) (A). GMT of Anti-RBD total Ig of SAR-CoV-2 at one month and three months after completing ChAdOx1-nCoV-19 vaccines among different types of anticancer treatments (B): immunotherapy, chemotherapy, targeted therapy.

SARS-CoV-2 binding antibody levels at 1 and 3 months after two doses of the ChAdOx-nCoV-19 vaccine in cancer patients stratified by treatment given (n = 137) compared to healthy controls (n = 84) (A). GMT of Anti-RBD total Ig of SAR-CoV-2 at one month and three months after completing ChAdOx1-nCoV-19 vaccines among different types of anticancer treatments (B): immunotherapy, chemotherapy, targeted therapy.